Compare Stocks: SNTI, GOSS, MREO, and ALGS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALGS Aligos Therapeutics	$5.80 +0.6%	$5.94	$3.98 ▼ $13.69	$37.66M	2.34	153,061 shs	2,462 shs
GOSS Gossamer Bio	$0.16 -8.8%	$0.17	$0.11 ▼ $3.87	$38.02M	2	18.42 million shs	6.91 million shs
MREO Mereo BioPharma Group	$0.26 +0.2%	$0.30	$0.20 ▼ $2.37	$40.72M	0.32	5.70 million shs	47,743 shs
SNTI Senti Biosciences	$0.32 +0.4%	$0.52	$0.31 ▼ $2.88	$9.87M	2.12	217,674 shs	10,969 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALGS Aligos Therapeutics	-7.25%	-5.42%	+3.04%	+11.63%	-48.15%
GOSS Gossamer Bio	+2.62%	+7.47%	+1.07%	+15.32%	-93.24%
MREO Mereo BioPharma Group	+1.84%	-7.99%	-14.07%	-16.44%	-85.78%
SNTI Senti Biosciences	-5.05%	-7.12%	-10.72%	-67.11%	-76.08%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALGS Aligos Therapeutics	$5.80 +0.6%	$5.94	$3.98 ▼ $13.69	$37.66M	2.34	153,061 shs	2,462 shs
GOSS Gossamer Bio	$0.16 -8.8%	$0.17	$0.11 ▼ $3.87	$38.02M	2	18.42 million shs	6.91 million shs
MREO Mereo BioPharma Group	$0.26 +0.2%	$0.30	$0.20 ▼ $2.37	$40.72M	0.32	5.70 million shs	47,743 shs
SNTI Senti Biosciences	$0.32 +0.4%	$0.52	$0.31 ▼ $2.88	$9.87M	2.12	217,674 shs	10,969 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALGS Aligos Therapeutics	-7.25%	-5.42%	+3.04%	+11.63%	-48.15%
GOSS Gossamer Bio	+2.62%	+7.47%	+1.07%	+15.32%	-93.24%
MREO Mereo BioPharma Group	+1.84%	-7.99%	-14.07%	-16.44%	-85.78%
SNTI Senti Biosciences	-5.05%	-7.12%	-10.72%	-67.11%	-76.08%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALGS Aligos Therapeutics	2.86	Moderate Buy	$38.50	564.25% Upside
GOSS Gossamer Bio	2.22	Hold	$3.20	1,851.22% Upside
MREO Mereo BioPharma Group	2.13	Hold	$1.67	553.59% Upside
SNTI Senti Biosciences	2.75	Moderate Buy	$10.00	3,054.57% Upside

Current Analyst Ratings Breakdown

Latest SNTI, GOSS, MREO, and ALGS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/27/2026	GOSS Gossamer Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/27/2026	GOSS Gossamer Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/19/2026	MREO Mereo BioPharma Group	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral ➝ Underweight
8/14/2026	GOSS Gossamer Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/11/2026	ALGS Aligos Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/11/2026	MREO Mereo BioPharma Group	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/11/2026	MREO Mereo BioPharma Group	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$1.00
8/10/2026	ALGS Aligos Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/28/2026	ALGS Aligos Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/28/2026	GOSS Gossamer Bio	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$1.00
7/27/2026	GOSS Gossamer Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy

(Data available from 9/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALGS Aligos Therapeutics	$31.52M	1.15	N/A	N/A	$8.67 per share	0.67
GOSS Gossamer Bio	$53.29M	0.72	N/A	N/A	($0.53) per share	-0.31
MREO Mereo BioPharma Group	$500K	81.44	N/A	N/A	$0.26 per share	0.98
SNTI Senti Biosciences	$55K	179.51	N/A	N/A	$0.18 per share	1.76

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALGS Aligos Therapeutics	-$24.19M	-$7.30	N/A	N/A	N/A	-241.01%	-160.72%	-92.30%	11/5/2026 (Estimated)
GOSS Gossamer Bio	-$170.37M	-$0.70	N/A	N/A	N/A	-235.00%	N/A	-112.04%	11/4/2026 (Estimated)
MREO Mereo BioPharma Group	-$41.88M	-$0.04	N/A	N/A	N/A	N/A	-74.82%	-64.28%	11/9/2026 (Estimated)
SNTI Senti Biosciences	-$61.44M	-$1.77	N/A	N/A	N/A	N/A	-1,629.80%	-119.72%	11/12/2026 (Estimated)

Latest SNTI, GOSS, MREO, and ALGS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	SNTI Senti Biosciences	-$0.33	-$0.41	-$0.08	-$0.41	N/A	$0.02 million
8/13/2026	Q2 2026	GOSS Gossamer Bio	-$0.1234	-$0.08	+$0.0434	-$0.08	$3.63 million	$9.24 million
8/12/2026	Q2 2026	MREO Mereo BioPharma Group	-$0.01	-$0.01	N/A	-$0.05	$3.50 million	N/A
8/6/2026	Q2 2026	ALGS Aligos Therapeutics	-$1.09	-$0.14	+$0.95	-$0.14	$24.68 million	$27.78 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALGS Aligos Therapeutics	N/A	N/A	N/A	N/A	N/A
GOSS Gossamer Bio	N/A	N/A	N/A	N/A	N/A
MREO Mereo BioPharma Group	N/A	N/A	N/A	N/A	N/A
SNTI Senti Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALGS Aligos Therapeutics	N/A	2.19	2.19
GOSS Gossamer Bio	N/A	0.53	0.53
MREO Mereo BioPharma Group	N/A	5.88	5.88
SNTI Senti Biosciences	N/A	0.83	0.83

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALGS Aligos Therapeutics	60.43%
GOSS Gossamer Bio	81.23%
MREO Mereo BioPharma Group	62.83%
SNTI Senti Biosciences	25.70%

Insider Ownership

Company	Insider Ownership
ALGS Aligos Therapeutics	7.80%
GOSS Gossamer Bio	3.74%
MREO Mereo BioPharma Group	6.50%
SNTI Senti Biosciences	3.12%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALGS Aligos Therapeutics	90	6.25 million	5.76 million	No Data
GOSS Gossamer Bio	180	234.70 million	225.92 million	Optionable
MREO Mereo BioPharma Group	40	159.69 million	149.31 million	Optionable
SNTI Senti Biosciences	4	31.15 million	30.17 million	Not Optionable

SNTI, GOSS, MREO, and ALGS Headlines

Recent News About These Companies

Senti Biosciences Holdings Inc

August 11, 2026 | cnn.com

Senti Biosciences Holdings, Inc. Announces a Strategic Transaction to Unlock Value for its Gene-Circuit-Enabled Pipeline, Including SENTI-202, and to Sharpen its Focus on Next ...

July 15, 2026 | markets.businessinsider.com

Senti Biosciences Holdings, Inc. Announces a Strategic Transaction to Unlock Value for its Gene-Circuit-Enabled Pipeline, Including SENTI-202, and to Sharpen its Focus on Next-Generation Controllable Genetic Medicines Powered by its Regulator Dial™ Technology Platform

July 15, 2026 | globenewswire.com

Senti Biosciences Faces Severe Refinancing and Liquidity Risks from Costly Note Structure

May 16, 2026 | tipranks.com

Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important ...

May 14, 2026 | markets.businessinsider.com $https://markets.businessinsider.com/news/stocks/senti-biosciences-holdings-announces-positive-fda-rmat-meeting-on-registrational-clinical-and-cmc-strategy-for-senti-202-in-relapsed-refractory-aml-along-with-important-efficacy-and-durability-1036155933$

Senti Biosciences Secures Up to $40 Million Financing and FDA Endorsement for SENTI-202 in Relapsed/Refractory Acute Myeloid Leukemia

May 14, 2026 | quiverquant.comQ

Senti Biosciences Holdings Reports First Quarter 2026 Financial Results and Highlights Advancement of SENTI-202 Program into Pivotal Phase

May 14, 2026 | globenewswire.com

Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important Efficacy and Durability Updates on the SENTI-202 Clinical Program

May 14, 2026 | globenewswire.com $https://www.globenewswire.com/news-release/2026/05/14/3294958/0/en/senti-biosciences-holdings-announces-positive-fda-rmat-meeting-on-registrational-clinical-and-cmc-strategy-for-senti-202-in-relapsed-refractory-aml-along-with-important-efficacy-an.html$

Senti Biosciences Holdings Inc.

May 13, 2026 | barrons.com

Senti Biosciences to Present on Logic-Gated Cell Therapies in Educational Session at AACR Annual Meeting 2026

April 13, 2026 | markets.businessinsider.com

Senti Biosciences to Present on Logic-Gated Cell Therapies in Educational Session at AACR Annual Meeting 2026

April 13, 2026 | globenewswire.com

Senti Biosciences Announces Publication in Cell Systems Demonstrating Advanced Logic-Gated CAR Design for Cell Therapies

April 1, 2026 | globenewswire.com

Senti Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update

March 27, 2026 | globenewswire.com

Senti Biosciences to Present Clinical and Translational Data on SENTI-202 at the 11th Annual Innate Killer Conference

March 23, 2026 | globenewswire.com

Senti Biosciences Amends Lease, Restructures GeneFab Sublease

March 19, 2026 | tipranks.com

Senti Biosciences to Present at Leerink Partners 2026 Global Healthcare Conference

March 3, 2026 | tmcnet.com

Senti Biosciences to Present at Leerink Partners 2026 Global Healthcare Conference

March 3, 2026 | globenewswire.com

Senti Biosciences to Showcase Gene Circuit Technology and Partnership Opportunities at TD Cowen Health Care Conference

February 24, 2026 | quiverquant.comQ

Senti Biosciences to Present at TD Cowen 46th Annual Health Care Conference

February 24, 2026 | globenewswire.com

Senti Bio Participates in Cell & Gene Live Event Highlighting Cutting-Edge Technologies Advancing Cell Therapy Development

February 20, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNTI, GOSS, MREO, and ALGS Company Descriptions

Aligos Therapeutics NASDAQ:ALGS

$5.80 +0.04 (+0.63%)

As of 09:50 AM Eastern

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Gossamer Bio NASDAQ:GOSS

$0.16 -0.02 (-8.84%)

As of 09:51 AM Eastern

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

Mereo BioPharma Group NASDAQ:MREO

$0.26 +0.00 (+0.16%)

As of 09:49 AM Eastern

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.

Senti Biosciences NASDAQ:SNTI

$0.32 +0.00 (+0.38%)

As of 09:44 AM Eastern

Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SNTI, GOSS, MREO, and ALGS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SNTI, GOSS, MREO, and ALGS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SNTI, GOSS, MREO, and ALGS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNTI, GOSS, MREO, and ALGS Company Descriptions

Aligos Therapeutics NASDAQ:ALGS

Gossamer Bio NASDAQ:GOSS

Mereo BioPharma Group NASDAQ:MREO

Senti Biosciences NASDAQ:SNTI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SNTI, GOSS, MREO, and ALGS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SNTI, GOSS, MREO, and ALGS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SNTI, GOSS, MREO, and ALGS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNTI, GOSS, MREO, and ALGS Company Descriptions

Aligos Therapeutics NASDAQ:ALGS

Gossamer Bio NASDAQ:GOSS

Mereo BioPharma Group NASDAQ:MREO

Senti Biosciences NASDAQ:SNTI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools